Only half of the patients improved and only up to a function level 35%.
From reading the document it describes only two patients in detail from the latest study and also the 3 pilot patients.
So the 35% may not be fully representative.
But there is definitely a large unknown associated with CTX.
While it may hopefully present a treatment option, for me I am hoping it can lead to more understanding of the disease.
If they can figure out the difference between the patients who don't respond to RTX and those who respond to CTX and also the non responders i imagine it will lead to a greater understanding of the disease and of RTX treatment too.
The only problem might be that CTX is so destructive it might be difficult to decipher exactly how it works in ME.
But it's another avenue to investigate and seeing as we dont have many, its very significant.